top of page

ASCO 2026: Known for its leadership in antibody-drug conjugates, Daiichi Sankyo's US CEO and new Head of Global R&D discuss ASCO data and investments it will be making throughout oncology

  • Jun 1
  • 1 min read

Ken Keller and John Tsai describe which other modalities besides ADCs that Daiichi thinks about, and cover ASCO and pipeline progress on Enhertu (Her2), Datroway (Trop2), the company's B7-H3.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page